Inhibition of cytosolic phospholipase A2α: Hit to lead optimization

Journal of Medicinal Chemistry

Volumn 49, Issue 1, 2006, Pages 135-158

  McKew, John C ^a   Foley, Megan A ^a   Thakker, Paresh ^a   Behnke, Mark L ^a   Lovering, Frank E ^a   Sum, Fuk Wah ^a   Tam, Steve ^a   Wu, Kun ^a   Shen, Marina W H ^a   Zhang, Wen ^a   Gonzalez, Mario ^b   Liu, Shanghao ^b   Mahadevan, Anu ^b   Sard, Howard ^b   Khor, Soo Peang ^a   Clark, James D ^a  

^a PFIZER INC   (United States)

^b ORGANIX INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [4 [[2 [5 CHLORO 1 (DIPHENYLMETHYL) 2 METHYL 1H INDOL 3 YL]ETHYL]SULFONYL]PHENYL]PROPANOIC ACID; 4 [2 [5 CHLORO 1 (DIPHENYLMETHYL) 2 METHYL 1H INDOL 3 YL]ETHOXY]BENZOATE; 4 [[2 [5 CHLORO 1 (DIPHENYLMETHYL) 2 METHYL 1H INDOL 3 YL]ETHYL]SULFONYL]BENZOIC ACID; 7 HYDROXYCOUMARINYL GAMMA LINOLENIC ACID; BENZOIC ACID DERIVATIVE; INDOLE DERIVATIVE; LINOLENIC ACID; LIPOXYGENASE INHIBITOR; PHOSPHOLIPASE A2 INHIBITOR; PHOSPHOLIPASE A2ALPHA INHIBITOR; PROSTAGLANDIN SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ACIDITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DETERMINATION; DRUG POTENCY; ENZYME INHIBITION; IC 50; LIPOPHILICITY; MALE; MICELLE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; CELL LINE; CELL PROLIFERATION; CYTOSOL; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HUMANS; INDOLES; MALE; MOLECULAR STRUCTURE; PHOSPHOLIPASES A; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 30444460888     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0507882     Document Type: Article

References (112)

1. FitzGerald, G. A.; Patrono, C. The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med. 2001, 345, 433-442.
2. Julius, D.; Basbaum, A. I. Molecular mechanisms of nociception. Nature 2001, 413, 203-210.
3. Woolf, C. J.; Salter, M. W. Neuroscience: Neuronal plasticity: Increasing the gain in pain. Science 2000, 288, 1765-1768.
4. Piomelli, D. The ligand that came from within. Trends Pharmacol. Sci. 2001, 22, 17-19.
5. Funk, C. D. Prostaglandins and leukotrienes: Advances in eicosanoid biology. Science 2001, 294, 1871-1875.
6. 4-receptor antagonist improves pulmonary function in patients with mild, chronic asthma. Am. Rev. Respir. Dis. 1989, 140, 1336-1339.
7. Israel, E. et al. The effect of inhibition of 5-lipoxygenase by Zileuton in mild-to-moderate asthma. Ann. Intern. Med. 1993, 119, 1059-1066.
8. Israel, E.; Cohn, J.; Dube, L.; Drazen, J. M. Effect of treatment with Zileuton, a 5-lipoxygenase inhibitor, in patients with asthma: A randomized controlled trial. J. Am. Med. Assoc. 1996, 275, 931-936.
9. 4 receptor antagonist, in subjects with bronchial asthma. Am. J. Respir. Crit. Care Med. 1994, 150, 618-623.
10. Reiss, T. F.; Altman, L. C.; Chervinsky, P.; Bewtra, A.; Stricker, W. E.; Noonan, G. P.; Kundu, S.; Zhang, J. Effects of Montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma. J. Allergy Clin. Immunol. 1996, 98, 528-534.
11. Liu, M. C.; Dube, L. M.; Lancaster, J. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: A 6-month randomized multicenter trial. J. Allergy Clin. Immunol. 1996, 98, 859-871.
12. Barnes, N. C.; Pujet, J. C. Pranlukast, a novel leukotriene receptor antagonist: Results of the first European, placebo controlled, multicentre clinical study in asthma. Thorax 1997, 52, 523-527.
13. Grossman, J.; Faiferman, I.; Dubb, J. W.; Tompson, D. J.; Busse, W.; Bronsky, E.; Montanaro, A.; Southern, L.; Tinkelman, D. Results of the first U.S. double-blind, placebo-controlled, multicenter clinical study in asthma with Pranlukast, a novel leukotriene receptor antagonist. J. Asthma 1997, 34, 321-328.
14. Reiss, T. F.; Chervinsky, P.; Dockhorn, R. J.; Shingo, S.; Seidenberg, B.; Edwards, T. B. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: A multicenter, randomized, double-blind trial. Arch. Intern. Med. 1998, 158, 1213-1220.
15. 2 receptor CRTH2: Structure, properties, and functions in leukocytes. Prostaglandins, Leukotrienes Essent. Fatty Acids 2003, 69, 169-177.
16. 2 into human airways during acute antigen challenge. N. Engl. J. Med. 1986, 315, 800-804.
17. 2 potentiates airway responsiveness to histamine and methacholine. Am. Rev. Respir. Dis. 1986, 133, 252-254.
18. 2-induced bronchoconstriction is mediated only in part by the thromboxane prostanoid receptor. Eur. Respir. J. 1995, 8, 411-415.
19. 2. Trends Immunol. 2004, 25, 40-46.
20. McIntyre, T. M.; Reinhold, S. L.; Prescott, S. M.; Zimmerman, G. A. Protein kinase C activity appears to be required for the synthesis of platelet-activating factor and leukotriene 84 by human neutrophils. J. Biol. Chem. 1987, 262, 15370-15376.
21. Ramesha, C. S.; Pickett, W. C. Platelet-activating factor and leukotriene biosynthesis is inhibited in polymorphonudear leukocytes depleted of arachidonic acid. J. Biol. Chem. 1986, 261, 7592-7595.
22. 2 activity regulates the synthesis of platelet-activating factor in granulocytic hl-60 cells. J. Biol. Chem. 1990, 265, 12363-12371.
23. Honda, Z. I., S.; Shimizu, T. J. Biochem. (Tokyo) 2002, 131, 773-779.
24. 2 inhibitors in development. Exp. Opin. Invesrig. Drugs 1997, 6, 279-298.
25. 2 inhibitors. Possible new antiinflammatory agents. Agents Actions Suppl. 1995, 46, 51-64.
26. 2 enzymes. Prostag. Other Lipid Mediat. 2002, 68-69, 3-58.
27. 2 gene in inbred mouse strains. J. Biol. Chem. 1995, 270, 22378-22385.
28. 2s in human neutrophils: Role in eicosanoid production and Gram-negative bacterial phospholipid hydrolysis. J. Biol. Chem. 2002, 277, 5061-5073.
29. 2 contains a calcium-dependent translocation domain with homology to PKC and GAP. Cell 1991, 65, 1043-1051.
30. Six, D. A.; Dennis, E. A. The expanding superfamily of phospholipase A(2) enzymes: Classification and characterization, Biochim. Biophys. Acta 2000, 1488, 1-19.
31. 2. J. Lipid Medial. Cell Signal. 1995, 12, 83-117.
32. 2. J. Biol. Chem. 1991, 266, 14850-14853.
33. 2 as defined by gene knockouts. Biochim. Biophys. Acta 2000, 1488, 139-148.
34. 2) function: Insights from the knockout mouse. Adv. Exp. Med. Biol. 2002, 507, 25-31.
35. 2α as revealed by gene-targeted mice. Prostaglandins Other Lipid Mediat. 2002, 68-69, 59-69.
36. 2. Nature 1997, 390, 622-625.
37. 2α- deficient mice are resistant to collagen-induced arthritis. J. Exp. Med. 2003, 197, 1297-1302.
38. 2 in allergic response and parturition. Nature 1997, 390, 618-622.
39. 2. Nat. Immunol. 2000, 1, 42-46.
40. Klivenyi, P.; Beal, M. F.; Ferrante, R. J.; Andreassen, O. A.; Wermer, M.; Chin, M.-R.; Bonventre, J. V. Mice deficient in group iv cytosolic phospholipase AT are resistant to MPTP neurotoxicity. J. Neurochem. 1998, 71, 2634-2637.
41. 2 in ischemic and toxic brain injury. Neurochem. Res. 2000, 25, 745-753.
42. 2 knockout mouse. J. Lipid Res. 2003, 44, 109-117.
43. 2 gene. J. Biol. Chem. 2000, 275, 34013-34016.
44. 2 suppresses ApcMin-induced tumorigenesis. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 3935-3939.
45. Griffiths, R. J. et al. Collagen-induced arthritis is reduced in 5-lipoxygenase-activating protein-deficient mice. J. Exp. Med. 1997, 185, 1123-1129.
46. Myers, L. K.; Kang, A. H.; Postlethwaite, A. E.; Rosloniec, E. F.; Morham, S. G.; Shlopov, B. V.; Goorha, S.; Ballou, L. R. The genetic ablation of cyclooxygenase 2 prevents the development of autoimmune arthritis. Arthritis Rheum. 2000, 43, 2687-2693.
47. Oshima, M.; Dinchuk, J. E.; Kargman, S. L.; Oshima, H.; Hancock, B.; Kwong, E.; Trzaskos, J. M.; Evans, J. F.; Taketo, M. M. Suppression of intestinal polyposis in ApcD716 knockout mice by inhibition of cyclooxygenase 2 (cox-2). Cell 1996, 87, 803-809.
48. Bombardier, C. et al. Comparison of upper gastrointestinal toxicity of Rofecoxib and Naproxen in patients with rheumatoid arthritis. New Engl. J. Med. 2000, 343, 1520-1528.
49. Silverstein, F. E. et al. Gastrointestinal toxicity with Celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The class study: A randomized controlled trial. J. Am. Med. Assoc. 2000, 284, 1247-1255.
50. Wallace, J. L. Nonsteroidal anti-inflammatory drugs and gastroenteropathy; The second hundred years. Gastroenterology 1997, 112, 1000-1014.
51. Wallace, J. L. Pathogenesis of NSAID-induced gastroduodenal mucosal injury. Best Pract. Res. Clin. Gastroenterol. 2001, 15, 691-703.
52. 4 synthesis in patients taking non-steroidal antiinflammatory drugs. Gut 1993, 34, 742-747.
53. Gyomber, E.; Vattay, P.; Szabo, S.; Rainsford, K. D. Effect of lipoxygenase inhibitors and leukotriene antagonists on acute and chronic gastric hemorrhagic mucosal lesions in ulcer models in the rat. J. Gastroenterol. Hepatol. 1996, 11, 922-927.
54. Vaananen, P. M.; Keenan, C. M.; Grisham, M. B.; Wallace, J. L. Pharmacological investigation of the role of leukotrienes in the pathogenesis of experimental NSAID gastropathy. Inflammation 1992, 16, 227-240.
55. Wallace, J. L. NSAID gastroenteropathy: Past, present and future. Can. J. Gastroenterol. 1996, 10, 451-459.
56. Unangst, P. C.; Connor, D. T.; Cetenko, W. A.; Sorenson, R. J.; Kostlan, C. R.; Sircar, J. C.; Wright, C. D.; Schrier, D. J.; Dyer, R. D. Synthesis and biological evaluation of 5-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl] methylene]oxazoles, -thiazoles, and -imidazoles: Novel dual 5-lipoxygenase and cyclooxygenase inhibitors with antiinflammatory activity. J. Med. Chem. 1994, 37, 322-328.
57. FitzGerald, G. A. Cox-2 and beyond: Approaches to prostaglandin inhibition in human disease. Nat. Rev. Drug Discover 2003, 2, 879-890.
58. Bresalier Robert, S. et al. Cardiovascular events associated with Rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 2005, 352, 1092-1102.
59. Solomon, S. D.; McMurray, J. J. V.; Pfeffer, M. A. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. 2005, 352, 1165.
60. FitzGerald, G. A. Coxibs and cardiovascular disease. N. Engl. J. Med. 2004, 351, 1709-1711.
61. Dogne, J.-M.; Supuran, C. T.; Pratico, D. Adverse cardiovascular effects of the coxibs. J. Med. Chem. 2005, 48, 2251-2257.
62. Vane, J. R. Biomedicine: Back to an aspirin a day? Science 2002, 296, 474.
63. Mukherjee, D.; Nissen, S. E.; Topol, E. J. Risk of cardiovascular events associated with selective cox-2 inhibitors. J. Am. Med. Assoc. 2001, 286, 954-959.
64. 2 inhibitors. Exp. Opin. Ther. Patents 2004, 14, 937-950.
65. 2. Abstracts of Papers, 223rd ACS National Meeting, Orlando, FL, April 7-11, 2002, MEDI-055.
66. 2 by methyl arachidonyl fluorophosphonate. Biochim. Biophys. Acta 1996, 1302, 55-60.
67. 2. J. Am. Chem. Soc. 1996, 118, 5519-5525.
68. 2 that acts at the lipid/water interface and possesses anti-inflammatory activity in skin inflammation models. J. Pharmacol. Exp. Ther. 2001, 298, 376-385.
69. 2 which acts in a competitive, reversible manner at the lipid/water interface. J. Enzymol. Inhib. 1998, 13, 195-206.
70. Trauner, D.; Churchill, D. G.; Danishefsky, S. J. The conformations of halichlorine and the pinnaic acids: Nitrogen inversion as a possible determinant of biological profile. Helv. Chim. Acta 2000, 83, 2344-2351.
71. Chou, T.; Kuramoto, M.; Otani, Y.; Shikano, M.; Yazawa, K.; Uemura, D. Pinnaic acid and tauropinnaic acid: Two novel fatty acids composing a 6-azaspiro[4.5]decane unit from the okinawan bivalve pinna muricata. Terrahedron Lett. 1996, 37, 3871-3874.
72. 2. Bioorg. Med. Chem. Lett. 2000, 10, 285-288.
73. 2. Bioorg. Med. Chem. Lett. 2001, 11, 2569-2572.
74. 2 as a target for drug design. Drugs Furure 2000, 25, 823-832.
75. 2-mediated arachidonic acid release in intact platelets. Arch. Pharm. 2003, 335, 547-555.
76. 2 inhibitors (Elan Pharmaceuticals). WO2000027824. 2000, p 49.
77. 2α, pyrrophenone. Biochem. J. 2002, 363, 727-735.
78. 2. J. Med. Chem. 2000, 43, 1041-1044.
79. 2. Part 2. Synthesis of potent and crystallized 4-triphenylmethylthio derivative 'pyrrophenone'. Bioorg. Med. Chem. Lett. 2001, 11, 587-590.
80. 2α blocks arachidonic acid release in a variety of mammalian cells. Biochim. Biophys. Acta 2001, 1513, 160-166.
81. 2α inhibitors: Substrate mimetics. Bioorg. Med. Chem. Lett. 2003, 13, 4501-4504.
82. 2-paradigm. Chem. Rev. 2001, 101, 2613-2653.
83. 2. Arch. Biochem. Biophys. 1999, 365, 239-247.
84. 2. Anal. Biochem. 1994, 222, 110-115.
85. Hagmann, W. Cell proliferation status, cytokine action and protein tyrosine phosphorylation modulate leukotriene biosynthesis in a basophil leukaemia and a mastocytoma cell line. Biochem. J. 1994, 299 (Pt 2), 467-472.
86. 2 based on a 1,3-disubstituted propan-2-one skeleton. J. Med. Chem. 2002, 45, 1348-1362.
87. Norman, P. IDrugs 1998, 1, 49-54.
88. 2, blocks production of arachidonate and 12-hydroxyeicosatetraenoic acid by calcium ionophore-challenged platelets. J. Biol. Chem. 1994, 269, 15619-15624.
89. Gribble, G. W. Recent developments in indole ring synthesis-methodology and applications. Perkin Trans. 1 2000, 1045-1075.
90. Hughes, D. L. Progress in the Fischer indole reaction. A review. Org. Prep. Proced. Int. 1993, 25, 607-632.
91. Mahadevan, A.; Sard, H.; Gonzalez, M.; McKew, J. C. A general method for c3 reductive alkylation of indoles. Tetrahedron Lett 2003, 44, 4589-4591.
92. Appleton, J. E.; Dack, K. N.; Green, A. D.; Steele, J. A mild and selective c-3 reductive alkylation of indoles. Tetrahedron Lett. 1993, 34, 1529-1532.
93. Chou, S.-Y. A novel substitution reaction of tetrahydropyrano[3,4-b] indole derivative - chain extension and structural correlation study. Heterocycles 2003, 60, 1095-1110.
94. 2. 1. Indole-3-acetamides. J. Med. Chem. 1996, 39, 5119-5136.
95. Ito, Y.; Sato, H.; Murakami, M. The first total synthesis of OPC-15161. J. Org. Chem. 1991, 56, 4864-4867.
96. Balsamini, C.; Diamantini, G.; Duranti, A.; Spadoni, G.; Tontini, A. A new synthesis of 2-substituted DL-tryptophan derivatives. Synthesis 1995, 370-372.
97. Abdel-Magid, A. F.; Carson, K. G.; Harris, B. D.; Maryanoff, C. A.; Shah, R. D. Reductive animation of aldehydes and ketones with sodium triacetoxyborohydride. Studies on direct and indirect reductive amination procedures. J. Org. Chem. 1996, 61, 3849-3862.
98. Mitsunobu, O. The use of diethyl azodicarboxylate and triphenylphosphine in synthesis and transformation of natural products. Synthesis 1981, 1-28.
99. Wolfe, J. P.; Singer, R. A.; Yang, B. H.; Buchwald, S. L. Highly active palladium catalysts for Suzuki coupling reactions. J. Am. Chem. Soc. 1999, 121, 9550-9561.
100. Wolfe, J. P.; Tomori, H.; Sadighi, J. P.; Yin, J.; Buchwald, S. L. Simple, efficient catalyst system for the palladium-catalyzed amination of aryl chlorides, bromides, and triflates. J. Org. Chem. 2000, 65, 1158-1174.
101. Ghomashchi, F. Biochim. Biophys. Acta 1999, 1420, 45-56.
102. 2 as a target for drug design Drugs Future 2000, 25, 823-832.
103. Matassa, V. G.; Maduskuie, T. P., Jr.; Shapiro, H. S.; Hesp, B.; Snyder, D. W.; Aharony, D.; Krell, R. D.; Keith, R. A. Evolution of a series of peptidoleukotriene antagonists: Synthesis and structure/activity relationships of 1,3,5-substituted indoles and indazoles. J. Med. Chem. 1990, 33, 1781-1790.
104. Taylor, E. C.; Liu, B. A simple and concise synthesis of LY231514 (MTA). Tetrahedron Lett. 1999, 40, 4023-4026.
105. Varney, M. D.; Romines, W. H.; Palmer, C. L.; Deal, J. G. Preparation of antiproliferative 5-thiapyrimidinone and 5-selenopyrimidinone glutamate compounds (Agouron Pharmaceuticals, Inc.). US Patent Application 1998; pp 21, Cont-in-part of US Ser. No. 991,259. abandoned.
106. Smith, K.; El-Hiti, G. A.; Pritchard, G. J.; Hamilton, A. Carbonylation of various organolithium reagents. A novel approach to heterocycles via intramolecular trapping of aromatic acyllithiums. J. Chem. Soc., Perkin Trans, 1 1999, 2299-2303.
107. Houlihan, W. J.; Parrino, V. A.; Uike, Y. Lithiation of n-(2-alkylphenyl)alkanamides and related compounds. A modified Madelung indole synthesis. J. Org. Chem. 1981, 46, 4511-4515.
108. Farren, C.; Christensen, C. A.; FitzGerald, S.; Bryce, M. R.; Beeby, A. Synthesis of novel phthalocyanine-tetrathiafulvalene hybrids; intramolecular fluorescence quenching related to molecular geometry. J. Org. Chem. 2002, 67, 9130-9139.
109. Garuti, L.; Giovanninetti, G.; Bova, S.; Chiarini, A. 1H-indole derivatives as calcium antagonists. Arch. Pharm. (Weinheim, Ger.) 1988, 321, 377-383.
110. Dess, D. B.; Martin, J. C. Readily accessible 12-i-5 oxidant for the conversion of primary and secondary alcohols to aldehydes and ketones. J. Org. Chem. 1983, 48, 4155-4156.
111. Madsen, P. et al. Optimization of alkylidene hydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6-tetra-methylbenzyl)-1H- indol-4-ylmethylene]hydrazide. J. Med. Chem. 2002, 45, 5755-5775.
112. 19F NMR spectroscopy. J. Combin. Chem. 2001, 3, 177-180.